Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome

Blood

Volumn 114, Issue 13, 2009, Pages 2753-2763

  Cabelof, Diane C ^a,b   Patel, Hiral V ^a   Chen, Qing ^b   Van Remmen, Holly ^c   Matherly, Larry H ^b,d   Ge, Yubin ^b,d   Taub, Jeffrey W ^b,d,e  

^a WAYNE STATE UNIVERSITY   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE BETA SYNTHASE; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR GATA 1; GATA1 PROTEIN, HUMAN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CHILD; CHROMOSOME 21; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; DNA DAMAGE; DNA REPAIR; DOWN SYNDROME; EXCISION REPAIR; FEMALE; FETUS; FOLATE METABOLISM; GENE DELETION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; GENETIC SUSCEPTIBILITY; GROUPS BY AGE; HOMEOSTASIS; HUMAN; LEUKEMIA; LEUKEMOGENESIS; MALE; MUTAGENESIS; MYELOPROLIFERATIVE DISORDER; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSIENT MYELOPROLIFERATIVE DISORDER; ACUTE MEGAKARYOCYTIC LEUKEMIA; CELL TRANSFORMATION; GENE DUPLICATION; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PHYSIOLOGY;

BASE SEQUENCE; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CYSTATHIONINE BETA-SYNTHASE; DNA MUTATIONAL ANALYSIS; DOWN SYNDROME; FEMALE; FETUS; GATA1 TRANSCRIPTION FACTOR; GENE DELETION; GENE DUPLICATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKEMIA, MEGAKARYOBLASTIC, ACUTE; MALE; MOLECULAR SEQUENCE DATA; MUTAGENESIS; MUTAGENESIS, INSERTIONAL;

EID: 70350492497     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-11-190330     Document Type: Article

References (54)

1. Taub JW. Relationship of chromosome 21 and acute leukemia in children with Down syndrome. J Pediatr Hematol Oncol. 2001;23:175-178. (Pubitemid 32332047)
2. Zipursky A, Thorner P, De Harven E, Christensen H, Doyle J. Myelodysplasia and acute megakaryoblastic leukemia in Down's syndrome. Leuk Res. 1994;18:163-171. (Pubitemid 24127571)
3. Zipursky A. Transient leukaemia - a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol. 2003;120:930-938. (Pubitemid 36411551)
4. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32:148-152. (Pubitemid 34977210)
5. Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood. 2003;101:4298-4300. (Pubitemid 36857792)
6. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101:4301-4304. (Pubitemid 36857793)
7. Rainis L, Bercovich D, Strehl S, et al. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood. 2003;102:981-986. (Pubitemid 36917793)
8. Groet J, McElwaine S, Spinelli M, et al. Acquired mutations in GATA1 in neonates with Down's syndrome with transient myeloid disorder. Lancet. 2003;361:1617-1620. (Pubitemid 36579001)
9. Xu G, Nagano M, Kanezaki R, Toki T, et al. Frequent mutations in the GATA1 gene in the transient myeloproliferative disorder of Down's syndrome. Blood. 2003;102:2960-2968. (Pubitemid 37248871)
10. Shimada A, Xu G, Toki T, Kimura H, Hayashi Y, Ito E. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome. Blood. 2004;103:366. (Pubitemid 38029962)
11. Taub JW, Mundschau G, Ge Y, et al. Prenatal origin of GATA1 mutations may be an initiating step in the development of leukemia in Down syndrome. Blood. 2004;104:1588-1589. (Pubitemid 39166547)
12. Bercovich D, Ganmore I, Scott LM, et al. Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet. 2008;372:1484-1492.
13. Finette BA, Rood B, Poseno T, Vacek P, Pueschel S, Homans AC. Atypical background somatic mutant frequencies at the HPRT locus in children and adults with Down syndrome. Mutat Res. 1998;403:35-43. (Pubitemid 28383645)
14. Taub JW, Huang X, Matherly LH, et al. Expression of chromosome 21-localized genes in acute myeloid leukemia: differences between Down syndrome and non-Down syndrome blast cells and relationship to in vitro sensitivity to cytosine arabinoside and daunorubicin. Blood. 1999;94:1393-1400. (Pubitemid 29380420)
15. Ge Y, Stout ML, Tatman DA, et al. GATA1, cytidine deaminase and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Institute. 2005;97:226-231. (Pubitemid 40277373)
16. Cabelof DC, Nakamura J, Heydari AR. A sensitive biochemical assay for the detection of uracil. Environ Mol Mutagen. 2006;47:31-37. (Pubitemid 43238022)
17. Cabelof DC, Guo Z, Raffoul JJ, et al. Base excision repair deficiency caused by polymerase beta haploinsufficiency: accelerated DNA damage and increased mutational response to carcinogens. Cancer Res. 2003;63:5799-5807. (Pubitemid 37187477)
18. Morrow JD, Roberts LJ 2nd. Mass spectrometry of prostanoids: F2-isoprostanes produced by non-cyclooxygenase free radical-catalyzed mechanism. Methods Enzymol. 1994;233:163-174. (Pubitemid 24177539)
19. Dar ME, Jorgensen TJ. Deletions at short direct repeats and base substitutions are characteristic mutations for bleomycin-induced double- and single-strand breaks, respectively, in a human shuttle vector system. Nucleic Acids Res. 1995;23:3224-3230.
20. Goodman MF, Fygenson DK. DNA polymerase fidelity: from genetics toward a biochemical understanding. Genetics. 1998;148:1475-1482.
21. Shibata A, Kamada N, Masumura K, et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene. 2005;24:1328-1337. (Pubitemid 40343113)
22. Ball EV, Stenson PD, Abeysinghe SS, Krawczak M, Cooper DN, Chuzhanova NA. Microdeletions and microinsertions causing human genetic disease: common mechanisms of mutagenesis and the role of local DNA sequence complexity. Human Mutat. 2005;26:205-213. (Pubitemid 41254376)
23. Sedwick WD, Brown OE, Glickman BW. Deoxyuridine misincorporation causes site-specific mutational lesions in the lacI gene of Escherichia coli. Mutat Res. 1986;162:7-20.
24. Fix DF, Glickman BW. Asymmetric cytosine deamination revealed by spontaneous mutational specificity in an Ung- strain of Escherichia coli. Mol Gen Genet. 1987;209:78-82.
25. Frederico LA, Kunkel TA. Shaw BR. A sensitive genetic assay for the detection of cytosine deaminastion: determination of rate constants and the activation energy. Biochemistry. 1990;29:2532-2537.
26. Impellizzeri KJ, Anderson B, Burgers PM. The spectrum of spontaneous mutations in a Saccharomyces cerevisiae uracil-DNA-glycosylase mutatant limits the function of this enzyme to cytosine deamination repair. J Bacteriol. 1991;173:6807-6810.
27. Duncan BK, Weiss B. Specific mutator effects of ung (Uracil-DNA Glycosylase) mutations in Escherichia coli. J Bacteriol. 1982;151:750-755. (Pubitemid 13230469)
28. Pogribna M, Melnyk S, Pogribny I, Chango A, Yi P, James SJ. Homocysteine metabolism in children with Down syndrome: in vitro modulation. Am J Hum Genet. 2001;69:88-95. (Pubitemid 32614021)
29. Kunz BA, Glickman BW. Mechanism of mutation by thymine starvation in Escherichia coli: clues from mutagenic specificity. J Bacteriol. 1985;162:859-864.
30. An Q, Robins P, Lindahl T, Barnes DE. C3T mutagenesis and -radiation sensitivity due to deficiency in the Smug1 and Ung DNA glycosylases. EMBO J. 2005;24:2205-2213.
31. Raji NS, Rao KS. Trisomy 21 and accelerated aging: DNA-repair parameters in peripheral lymphocytes of Down's syndrome patients. Mech Ageing Dev. 1998;100:85-101.
32. Agarwal SS, Blumberg BS, Gerstley BJ, London WT, Sutnick AI, Loeb LA. DNA polymerase activity as an index of lymphocyte stimulation: studies in Down's syndrome. J Clin Invest. 1970;49:161-169.
33. Athanasiou K, Sideris EG, Bartsocas C. Decreased repair of x-ray induced DNA single-strand breaks in lymphocytes in Down's syndrome. Pediatr Res. 1980;14:336-338. (Pubitemid 10156097)
34. Smrcek JM, Baschat AA, Germer U, Gloeckner-Hofmann K, Gembruch U. Fetal hydrops and hepatosplenomegaly in the second half of pregnancy: a sign of myeloproliferative disorder in fetuses with trisomy 21. Ultrasound Obstet Gynecol. 2001;17:403-409. (Pubitemid 32499871)
35. Robertson M, De Jong G, Mansvelt E. Prenatal diagnosis of congenital leukemia in a fetus at 25 weeks' gestation with Down syndrome: case report and review of the literature. Ultrasound Obstet Gynecol. 2003;21:486-489. (Pubitemid 36605713)
36. Pallardo FV, Degan P, d'Ischia M, et al. Multiple evidence for an early age pro-oxidant state in Down syndrome patients. Biogerontology. 2006;7:211-220. (Pubitemid 44237302)
37. Zitnanová I, Sumegova K, Simko M, et al. Protein carbonyls as a biomarker of foetal-neonatal hypoxic stress. Clin Biochem. 2007;40:567-570 (Pubitemid 46601415)
38. Praticò D, Iuliano L, Amerio G, et al. Down's syndrome is associated with increased 8,12-isoi-PF2alpha-VI levels: evidence for enhanced lipid peroxidation in vivo. Ann Neurol. 2000;48:795-798.
39. Yao Y, Zhukareva V, Sung S, et al. Enhanced brain levels of 8,12-iso-iPF2alpha-VI differentiate AD from frontotemporal dementia. Neurology. 2003;61:475-478.
40. Irizarry MC, Hyman BT. Brain isoprostanes: a marker of lipid peroxidation and oxidative stress in AD. Neurology. 2003;61:436-437.
41. Perrone S, Longini M, Bellieni CV, et al. Early oxidative stress in amniotic fluid of pregnancies with Down syndrome. Clin Biochem. 2007;40:177-180. (Pubitemid 46108711)
42. Mosharov E, Cranford MR, Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry. 2000;39:13005-13011. (Pubitemid 30825904)
43. Vitvitsky V, Dayal S, Stabler S, et al. Perturbations in homocysteine-linked redox homeostasis in a murine model for hyperhomocysteinemia. Am J Physiol Regul Intergr Comp Physiol. 2004;287:R39-46. (Pubitemid 38856309)
44. Feo F, Pascale R, Garcea R, et al. Effect of the variations of S-adenosyl-L-methionine liver content on fat accumulation and ethanol metabolism in ethanol-intoxicated rats. Toxicol Appl Pharmacol. 1986;83:331-341. (Pubitemid 16079418)
45. Muchová J, Sustrova M, Garaiova I, et al. Influence of age on activities of antioxidant enzymes and lipid peroxidation products in erythrocytes and neutrophils of Down syndrome patients. Free Radic Biol Med. 2001;31:499-508. (Pubitemid 32728437)
46. Lee M, Hyun D. Jenner P, Halliwell B. Effect of overexpression of wild-type and mutant Cu/Zn-superoxide dismutases on oxidative damage and antioxidant defences: relevance to Down's syndrome and familial amyotrophic lateral sclerosis. J Neurochem. 2001;76:957-965. (Pubitemid 32167369)
47. Meguid NA, Kholoussi NM, Afifi HH. Evaluation of superoxide dismutase and glutathione peroxidase enzymes and their cofactors in Egyptian children with Down's syndrome. Biol Trace Elem Res. 2001;81:21-28.
48. Taub JW, Konrad MA, Ge Y, et al. High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood. 2002;99:2992-2996. (Pubitemid 34525390)
49. Blatt J, Albo V, Prin W, et al. Excessive chemotherapy-related myleotoxicity in children with Down's syndrome and acute lymphoblastic leukemia. Lancet. 1986;2:914. (Pubitemid 17170655)
50. Peeters M, Poon A. Down syndrome and leukaemia: unusual clinical aspects and unexpected methotrexate sensitivity. Eur J Pediatr. 1987;146:416-422. (Pubitemid 17130864)
51. Peeters MA, Rethore MO, Lejeune J. In vivo folic acid supplementation partially corrects in vitro methotrexate toxicity in patients with Down syndrome. Br J Haematol. 1995;89:678-680.
52. Kamen BA, Nylen PA, Camitta BM, et al. Methotrexate accumulation and folate depletion in cells as a possible mechanism of chronic toxicity to the drug. Br J Haematol. 1981;49:355-360.
53. Tunstall-Pedoe O, Roy A, Karadimitris A, et al. Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood. 2008;112:4507-4511.
54. De Vita S, Devoy A, Groet J, et al. Megacaryocyte hyperproliferation without GATA1 mutation in foetal liver of a case of Down syndrome with hydrops foetalis. Br J Haematol. 2008;143:300-303.